secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-07-24T20:51:25+00:00
Accession:  0001104659-26-086674
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma receives Nasdaq notice of non-compliance with Bid Price Rule; Panel to decide on continued listing
--------------------------------------------------------------------------------

- Received Nasdaq notice on July 20, 2026 that it has not regained compliance with $1 minimum bid price rule and is not eligible for second 180-day extension.
- Nasdaq Hearings Panel will consider this deficiency in decision on continued listing; company must submit written view by July 27, 2026.
- Company filed definitive proxy for August 3, 2026 annual meeting to authorize reverse stock split, a potential cure for bid price deficiency.
- No assurance that Panel will grant additional time or that company will regain compliance with Nasdaq listing rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926086674/0001104659-26-086674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926086674/tm2621298d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-086674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer